CTY公司概覽
盤中時間採用ET。市場資料可能有所延遲。
公司概況
公司網站City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
- 產業
- Biotechnology
- 部門
- Healthcare
- 總部
- US
- 上市以來
- 2026年10月16日
- 僱員
- 75
市場位置
日內區間
目前US$22.40
52週區間
目前US$22.40
- 開盤價
- US$21.88
- 前收盤價
- US$18.00
- 成交量
- 140.64萬
- 1.53× 平均值
- 平均成交量
- 92.01萬
- 日均成交量
- 市值
- 2.18億 USD
- 貝塔
- 0
- 市場參考 1
- 50天平均值
- US$22.40
- 處於平均水準
- 200天平均值
- US$22.40
- 處於平均水準
